Search

Search Constraints

You searched for: Author/Creator Yamada, Ren

Search Results

1. Baseline angiopoietin‐2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. Issue 5 (11th April 2020)

2. Changes in the estimated renal function after hepatitis C virus eradication with direct‐acting antiviral agents: Impact of changes in skeletal muscle mass. Issue 5 (24th February 2021)

3. Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. Issue 9 (20th July 2021)

4. Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon‐lambda 3 induction in chronic hepatitis B patients. Issue 7 (12th April 2022)

5. High serum angiopoietin‐2 level predicts non‐regression of liver stiffness measurement‐based liver fibrosis stage after direct‐acting antiviral therapy for hepatitis C. Issue 6 (18th February 2020)

6. Incidence of post‐transplant hepatitis B virus reactivation with the use of kidneys from donors with resolved hepatitis B virus infection. Issue 11 (7th September 2022)

7. Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1–3 signaling, but not FGFR4 signaling. (25th May 2020)

8. Overestimated renal function in patients with liver cirrhosis predicts poor prognosis. Issue 7 (19th April 2022)

9. Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy‐associated hepatitis in Japan. Issue 10 (31st March 2020)

10. Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation‐related hepatitis. Issue 2 (10th January 2023)